Indiana Biosciences Research Institute Names New Board Members

November 09, 2020

Eight new members join the Board of Directors; bringing Board to 14

Indianapolis, Ind. – The Indiana Biosciences Research Institute (IBRI), a leading industry-inspired applied research institute, is pleased to announce the addition of eight members to its Board of Directors. Its new members represent industry, academia and government, showing the IBRI’s continued commitment to be a catalyst for collaboration to discover and develop innovative solutions to improve human health.

“We’re pleased to add these life sciences leaders to our Board,” said Daniel Evans, Jr., chairman of the IBRI Board of Directors. “These new Board members value the tremendous work our scientists have already initiated and are eager to help the organization achieve its goal to emerge as a key leader of innovative translational science that focuses on improving health outcomes in Indiana and the world.”

New Board members include:

  • Bob Bernhard – Vice President for Research, University of Notre Dame
  • Ken Custer – Vice President, Portfolio Strategy, Chief of Staff, Lilly Research Labs, Eli Lilly and Company
  • Tatiana Foroud – Executive Associate Dean for Research Affairs, IU School of Medicine
  • Jay Hess – Executive Vice President for University Clinical Affairs and Dean of the Indiana University (IU) School of Medicine
  • Cris Johnston – Director of the Indiana Office of Management and Budget
  • Theresa Mayer – Executive Vice President for Research and Partnerships, Purdue University
  • Aaron Schacht – Executive Vice President, Innovation, Regulatory and Business Development, Elanco
  • Wendy Srnic – Global Leader, Integrated Field Sciences, Corteva

The IBRI welcomes its new Board members, while also saying farewell to Kristina Box, MD, FACOG, Indiana State Health Commissioner, and Jon Serbousek, Mid-Tech Industry Advisor, Board Advisor, who are stepping down. “We are grateful to Kristina and Jon for their dedication to our organization and service to our Board,” said Evans.

About the Indiana Biosciences Research Institute

The Indiana Biosciences Research Institute (IBRI) is an independent, nonprofit discovery science and applied research institute currently targeting diabetes, metabolic disease, poor nutrition and related health data science.  Inspired by Indiana’s leading life sciences companies, research universities and philanthropic community, the IBRI is building a world-class organization of researchers, innovators and entrepreneurs to catalyze scientific discovery and its applications, resulting in improved health outcomes for Indiana patients and beyond. For more information about the IBRI, visit